계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
ABAC Therapeutics
company
About
ABAC Therapeutics (ABAC) develops new targeted antibiotics for patients with severe infections.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- €16M
- Industries
- Biotechnology,Life Science,Therapeutics
- Founded date
- Jan 1, 2014
- Number Of Employee
- 1 - 10
- Operating Status
- Active
ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximize the chance of success in clinical development.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€16M
ABAC Therapeutics has raised a total of
€16M
in funding over 2 rounds. Their latest funding was raised on
Feb 15, 2018 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 15, 2018 | Series A | €16M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
ABAC Therapeutics is funded by 1 investors.
Global health sciences venture fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
